Cardiology CNE/CPE/CME Course 3 | HCM Around the Globe: Not an Isolated Issue

Program Description

Hypertrophic cardiomyopathy (HCM) is an under-recognized, common, and treatable genetic disease occurring worldwide. HCM is a myocardial disorder most often caused by mutations in one of several sarcomere genes that encode components of the contractile apparatus of the heart. It is characterized by ventricular hypertrophy that cannot be explained by another cardiac or systemic disease. Adding to the burden of disease, HCM can present with a variety of symptoms mimicking other conditions and may go undiagnosed for many years and it is estimated that approximately one in 500 individuals in the United States may have clinically unrecognized, undiagnosed HCM, with an overall prevalence estimated at 750,000.

Please join Dr. Maron and Dr. Torres in this first installment of a CMEO Snack series as they discuss strategies for optimal screening of HCM in an effort to increase recognition and diagnosis of this too often misdiagnosed disease.

Educational Objectives

Upon completion, participants should be able to:

• Assess safety and efficacy of emerging agents.

Intended Audience

Cardiologists, interventional cardiologists, electrophysiologists, cardiac surgeons (Secondary: Primary care physicians/General practitioners, PAs, nurse practitioners, nurses, and pharmacists).

Commercial Supporter

Supported by an educational grant from Bristol Myers Squibb.

Max Credits

• 0.50 / AMA PRA Category 1 Credit
• 0.50 / ABIM MOC Point
• 0.50 / AAPA Category 1 CME Credit
• 0.50 / ANCC Contact Hour
• 0.50 / CE for Pharmacists

Expires: May 10, 2023